[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100413113":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":51,"collaborators":56,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":10,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":10,"enrollmentInfo":70,"targetDuration":10,"studyType":73,"phases":10,"briefSummary":74,"conditions":75,"keywords":10,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"University of Aarhus","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1",null,"Patients treated for metastatic renal cell carcinoma in Denmark over a 6-year period.",[13],"Other: Measurement of concentration of active metabolite in cancer treatment.",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Measurement of concentration of active metabolite in cancer treatment.","Medical treatment for metastatic renal cell carcinoma with axitinib, cabozantinib, pazopanib, sorafenib, sunitinib, tivozanib and ipilimumab and nivolumab.",[9],[20],"Measurement of autoantibodies and receptor polymorfia for CTLA-4 and PD-1 inhibition.",[22],{"name":23,"affiliation":5,"role":24},"Niels Fristrup, MD, PhD","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":10,"email":29},"CONTACT","+4520914161","niels.fristrup@rm.dk",{"name":31,"role":27,"phone":32,"phoneExt":10,"email":33},"Jakob N Henriksen, MD","+4540438804","jakob.n.henriksen@oncology.au.dk",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Department of Oncology, Aarhus University Hospital","RECRUITING","Aarhus","Danmark","8200","Denmark","DK",{"type":44,"coordinates":45},"Point",[46,47],10.21076,56.15674,{"lat":47,"lon":46},[50],{"name":23,"role":27,"phone":28,"phoneExt":10,"email":29},{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":55,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Niels Fristrup","MD PhD","Aarhus University Hospital",[57,59],{"name":58,"class":6},"Herlev Hospital",{"name":60,"class":6},"Rigshospitalet, Denmark","100413113","tdm-for-optimized-outcome-in-patients-with-mrcc-100413113",false,"NCT04659343","TDM for Optimized Outcome in Patients With mRCC.","Therapeutic Drug Monitoring for Optimized Outcome in Patients With Metastatic Renal Cell Carcinoma","Inclusion Criteria:\n\n* Patients in Denmark with medically treated metastatic renal cell carcinoma.\n\nExclusion Criteria:\n\n* No written informed consent.","ALL","18 Years",{"count":71,"type":72},200,"ESTIMATED","OBSERVATIONAL","The purpose of this observational study is to assess the role of plasma concentration monitoring of treatment drugs for patients with metastatic renal cell carcinoma (mRCC) in terms of efficacy and side effects. It furthermore holds microbiome characterization of CPI-treated patients.\n\nFurthermore, the investigators examines the role of anti-drug antibodies and receptor polymorphisms in CTLA-4 and PD-1 receptors in treatment failure among patients with mRCC treated with check point immunotherapy (CPI). Moreover, polymorphisms in the UGT1A1 gene will be correlated with the pazopanib treatment dose.",[76,77,78,79,80],"Kidney Cancer","Renal Cell Carcinoma Metastatic","Drug Toxicity","Drug Side Effect","Drug Mechanism","2026-04-28",{"date":83,"type":84},"2026-05-04","ACTUAL",{"date":86,"type":84},"2020-11-01",{"date":88,"type":72},"2029-08-31",{"name":53,"class":6},1]